Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBASH3B | Q8TF42 | 1/20 | 0.98 |
| ▸ | PPARG | P37231 | 1/20 | 0.55 |
| ▸ | ITGB2 | P05107 | 6/20 | 0.54 |
| ▸ | ICAM1 | P05362 | 6/20 | 0.54 |
| ▸ | ITGAL | P20701 | 6/20 | 0.54 |
| ▸ | F11 | P03951 | 2/20 | 0.54 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.53 |
| ▸ | TACR1 | P25103 | 2/20 | 0.52 |
| ▸ | CCKBR | P32239 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rebamipide SCHEMBL23346201 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL5794018 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL21623658 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL29560992 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL221527 | 0.99 | UBASH3B (1.00) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL2292009 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL9114879 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL27858766 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL28798513 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL | |
| Rebamipide SCHEMBL27819911 | 0.98 | UBASH3B (0.98) | UBASH3BPPARGITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102174015-B | Refining method of rebamipide | JIANGXI SYNERGY PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | claimed |
| CN-114588156-B | Ophthalmic preparation and application thereof in treating presbyopia | 温州医科大学附属眼视光医院 | 2024-06-11 | — | — | CN | disclosed |
| WO-2023202705-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATING PRESBYOPIA | 温州医科大学附属眼视光医院 | 2023-10-26 | — | — | WO | disclosed |
| CN-114588156-A | Ophthalmic preparation and application thereof in treating presbyopia | 温州医科大学附属眼视光医院 | 2022-06-07 | — | — | CN | disclosed |
| CN-104418802-B | rebamipide monohydrate crystal form and preparation method thereof | 重庆汇智药物研究院有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104230798-B | Preparation method of rebamipide | 重庆圣华曦药业股份有限公司 | 2017-02-15 | — | — | CN | disclosed |
| CN-104418802-A | Rebamipide monohydrate crystal form and preparation method thereof | CHONGQING HUIZHI PHARMACEUTICAL RES INST CO LTD | 2015-03-18 | — | — | CN | disclosed |
| CN-104230798-A | Preparation method of high-purity rebamipide | CHONGQING SHENGHUAXI PHARMA CO | 2014-12-24 | — | — | CN | disclosed |
| CN-103920138-A | Medicinal composition as well as preparation and application thereof | Zhaoke pharmaceutical guangzhou co ltd | 2014-07-16 | — | — | CN | disclosed |
| CN-102174015-B | Refining method of rebamipide | JIANGXI SYNERGY PHARMACEUTICAL CO LTD | 2013-10-16 | — | — | CN | disclosed |
| CN-102512420-A | Officinal composite using Rebamipide officinal salt as active ingredient | BEIJING FUKANGREN BIOPHARMACEUTICAL TECHNOLOGY CO LTD | 2012-06-27 | — | — | CN | disclosed |
| CN-102174015-A | Refining method of rebamipide | JIANGXI SYNERGY PHARMACEUTICAL CO LTD | 2011-09-07 | — | — | CN | disclosed |